Skip to main content

ARIIA for Pharmaceuticals

From trial data to commercial intelligence

Pharmaceutical enterprises sit on mountains of clinical, regulatory, and commercial data that rarely connects. ARIIA unifies trial data, HCP engagement, market access, and manufacturing quality into one intelligent layer.


Key Use Cases

  • Clinical trial intelligence and enrollment optimization
  • HCP (Healthcare Provider) engagement scoring and commercial performance
  • Supply chain and cold-chain visibility across global distribution
  • Regulatory document intelligence and submission readiness
  • Pharmacovigilance signal detection across adverse event data

Data Sources ARIIA Connects

System TypeExamples
ClinicalTrial management systems, EDC platforms, site performance data
RegulatoryeCTD submission systems, dossier repositories, safety databases
CommercialHCP engagement platforms, sales force data, market access data
Supply chainCold-chain monitoring, distribution systems, CMO data
SafetyAdverse event databases, signal detection systems, CIOMS forms

Outcomes

MetricResultHow
Faster regulatory submission prep40%Document intelligence across clinical, safety, and CMC data — unified for dossier readiness
Better trial enrollment visibilitySite performance, patient eligibility, and protocol deviations unified in one view
Reduction in manual safety reporting72%Automated signal detection and case narrative generation from adverse event feeds

Example Intelligence Queries

  • "Which trial sites are at risk of enrollment shortfall in the next 30 days?"
  • "What adverse event signals have emerged across the Phase 3 data this month?"
  • "Show me HCP engagement by region and identify the lowest-performing territories"
  • "What is the submission readiness status for Module 2 of the NDA dossier?"

Regulatory note: ARIIA provides intelligence and automation support for regulatory processes. Regulatory submissions remain the responsibility of the qualified regulatory affairs team. All ARIIA-generated content must be reviewed by qualified personnel before inclusion in regulatory submissions.